Should MRI be the primary endpoint of phase III trials in MS? No

被引：0
|
作者：
Weinshenker, B. G. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
107
引用
收藏
页码：28 / 28
页数：1
相关论文
共 50 条
  • [31] Section III - Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism? Section III discussion
    Black, DM
    Orloff, DG
    Bilheimer, DW
    Shepherd, J
    Olsson, AG
    Sacks, FM
    Paoletti, R
    Catapano, A
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (8A): : 92F - 94F
  • [32] Quality of life as a primary endpoint in ovarian cancer trials
    Mahner, Sven
    Burges, Alexander
    LANCET ONCOLOGY, 2014, 15 (04): : 363 - 364
  • [33] A potential primary endpoint for clinical trials in glaucoma neuroprotection
    De Moraes, Carlos Gustavo
    Lane, Keith J. J.
    Wang, Xiao
    Liebmann, Jeffrey M. M.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [34] Clostridium difficile infection trials: what is the primary endpoint?
    Guery, Benoit
    LANCET INFECTIOUS DISEASES, 2019, 19 (03): : 219 - 220
  • [35] A potential primary endpoint for clinical trials in glaucoma neuroprotection
    Carlos Gustavo De Moraes
    Keith J. Lane
    Xiao Wang
    Jeffrey M. Liebmann
    Scientific Reports, 13
  • [36] MRI monitoring of MS in clinical trials
    Miller, DH
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2002, 104 (03) : 236 - 243
  • [37] ADOPT (A Dynamic HbA1c EndpOint Prediction Tool): A framework for Predicting Primary Endpoint in Phase 3 Diabetes Trials
    Moller, Jonas B.
    Overgaard, Rune V.
    Kjellson, Maria C.
    Kristensen, Niels R.
    Klim, Soren
    Ingwersen, Steen H.
    Karlsson, Mats O.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S57 - S58
  • [38] Should clinical trials about prostate cancer assess the frailty as an endpoint?
    Irfan Karahan
    Didem Sener Dede
    International Urology and Nephrology, 2023, 55 : 1729 - 1730
  • [39] Should clinical trials about prostate cancer assess the frailty as an endpoint?
    Karahan, Irfan
    Dede, Didem Sener
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (07) : 1729 - 1730
  • [40] Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (09) : 1068 - 1069
12345